Generic Medicine Info
Should be taken on an empty stomach. Take on an empty stomach 1 hr before meals.
Advanced arteriosclerosis, hyperthyroidism, severe hypertension, pulmonary hypertension, glaucoma, agitated states; history of drug abuse. Concomitant use with other anorectic agents; during or within 14 days of discontinuing MAOI.
Special Precautions
Patient with hypertension or symptomatic CV disease, including arrhythmias; pre-existing psychosis or bipolar disorders, history of seizure disorders, Tourette's syndrome, diabetes mellitus. Renal and hepatic impairment. Elderly. Pregnancy and lactation. Not recommended for use in patients who have used other anorectic agents within the prior year. Avoid abrupt withdrawal. Patient Counselling This drug may cause CNS effects that may impair your mental alertness or physical coordination; if affected, do not drive or operate machinery. Monitoring Parameters Perform baseline cardiac evaluation to detect pulmonary hypertension or pre-existing valvular heart disease before treatment initiation. Monitor echocardiogram during and after treatment; blood pressure, heart rate, weight, waist circumference, renal function (in elderly).
Adverse Reactions
Significant: Heart failure, valvular heart disease, new-onset psychosis or mania, toxic psychosis, induction of mixed/manic episodes, hallucinations (high doses), increased convulsions, CNS effects; drug abuse, tolerance, or dependence (prolonged use); withdrawal symptoms. Rarely, cardiac valvulopathy. Blood and lymphatic system disorders: Agranulocytosis, leucopenia. Cardiac disorders: Arrhythmia, tachycardia, palpitation, precordial pain, dyspnoea. Eye disorders: Blurred vision, mydriasis. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, constipation abdominal discomfort, dysgeusia, xerostomia. General disorders and administration site conditions: Malaise, jitteriness. Investigations: ECG changes. Musculoskeletal and connective tissue disorders: Myalgia. Nervous system disorders: Headache, drowsiness, dizziness, restlessness, dyskinesia, tremor, cerebrovascular accident. Psychiatric disorders: Insomnia, anxiety, euphoria, depression, nervousness, dysphoria. Renal and urinary disorders: Dysuria, polyuria. Reproductive system and breast disorders: Impotence, gynaecomastia, changes in libido, menstrual irregularity. Skin and subcutaneous tissue disorders: Rash, urticaria, erythema, ecchymoses, alopecia, increased sweating. Vascular disorders: Hypertension.
Potentially Fatal: Primary pulmonary hypertension.
Drug Interactions
Effects may be potentiated by sedatives. May cause arrhythmias with general anaesthetics. May alter the drug requirements of antidiabetics (e.g. insulin). May interfere with the effects of antihypertensives (e.g. guanethidine, α-methyldopa). Anorectic effects may be antagonised by phenothiazines.
CIMS Class
ATC Classification
A08AA03 - amfepramone ; Belongs to the class of centrally acting antiobesity products. Used in the treatment of obesity.
Disclaimer: This information is independently developed by CIMS based on amfepramone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in